---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-007826"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:16:09.282751+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q1 revenue $11.6M (+78% YoY); raises 2022 core revenue guidance to at least 25%

## Summary
- Total revenue $11.6M, up 78% YoY; core business revenue $9.6M, up 48% YoY driven by cell therapy customers (+57%).
- SPL Program-related revenue $2.0M vs immaterial; total SPLs now 16 with Intima Bioscience addition.
- Net loss narrowed to $4.1M from $7.1M; EBITDA loss $3.7M vs $6.4M.
- Raises 2022 core revenue guidance to at least 25% growth; reiterates SPL milestone revenue ~$4M.
- Cash and investments $246.3M as of March 31, 2022.

## SEC filing metadata
- accession: 0001558370-22-007826
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837022007826/0001558370-22-007826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837022007826/mxct-20220509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-007826
- JSON: https://secwatch.observer/filing/0001558370-22-007826.json
- Plain text: https://secwatch.observer/filing/0001558370-22-007826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.